Durable response in a woman with recurrent low-grade endometrioid endometrial cancer and a germline BRCA2 mutation treated with a PARP inhibitor

Allison A Gockley,David L Kolin,Christopher S Awtrey,Neal I Lindeman,Ursula A Matulonis,Panagiotis A Konstantinopoulos

doi:10.1016/j.ygyno.2018.05.028

Durable response in a woman with recurrent low-grade endometrioid endometrial cancer and a germline BRCA2 mutation treated with a PARP inhibitor

Allison A Gockley, David L Kolin + Show 4 more

Open Access

https://doi.org/10.1016/j.ygyno.2018.05.028

Copy DOI

Journal: Gynecologic oncology	Publication Date: Jun 22, 2018
Citations: 18

Affiliation: Brigham and Women's Hospital, Beth Israel Deaconess Medical Center, Dana-Farber Cancer Institute, Harvard University

#Poly (ADP Ribose) Polymerase Inhibitor #Germline BRCA2 Mutation + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

A 42-year-old woman with a germline BRCA2 mutation and recurrent low-grade endometrioid endometrial adenocarcinoma experienced clinical and radiographic response to the poly (ADP ribose) polymerase (PARP) inhibitor, olaparib. Molecular and treatment factors are discussed.

Full Text